1. Generics Bulletin
  2. >>Business
  3. >>Strategy

US Biosimilars ‘Bumpy’ For Teva As It Prepares For Alvotech Inspection

CEO Hints At More Deals On The Horizon Despite A Degree Of Market Uncertainty

 
• By Dave Wallace

Offering the latest details on Teva’s biosimilars strategy, CEO Richard Francis spoke about how the firm is looking to bring Alvotech’s FDA filings to the finish line as well as hinting at future biosimilars partnership deals. At the same time, he acknowledged a “bumpy” US market with a degree of uncertainty that has led the firm to allocate capital accordingly.

Road sign warning of bumps ahead
Teva’s CEO sees the US market as “bumpy” • Source: Shutterstock

Teva’s management has expressed confidence in helping to resolve manufacturing issues at its US biosimilars partner Alvotech and has also hinted at new biosimilars deals on the horizon in the near future. However, at the same time the firm’s CEO acknowledged that the “bumpy” US market was still carrying a degree of uncertainty that is leading the firm to allocate capital accordingly.

During the firm’s third-quarter results presentation (see sidebar), president and CEO Richard Francis provided updates on Teva’s biosimilars interests, in particular its US partnership with Alvotech that has so far

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Business